{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 50 of 122', '8.5 Special Safety Considerations', 'This section provides guidelines for the assessment of allergic reactions (including', 'assessment of anaphylaxis and tolerability of a dose), treatment of allergic reactions, study', 'product dose adjustments due to allergic reactions or other reasons, missed doses of study', 'product, adverse events of interest, and other notable events (overdose, pregnancy and other', 'reproductive considerations). The assessment and treatment of allergic reactions resulting', 'from accidental and nonaccidental food allergen exposure should follow the same guidelines', 'as allergic reactions resulting from study product.', '8.5.1', 'Assessment of Allergic Reactions', 'Allergy symptoms may occur during AR101 treatment as observed in other desensitization', 'protocols. Subjects must be observed for at least 90 minutes after completion of a dose or', 'dose escalation at the study site, with vital sign measurements (blood pressure and heart rate)', 'and assessment for symptoms of allergic reaction performed every 30 minutes. The postdose', 'observation period may be shortened to 30 minutes during maintenance if no allergy', 'symptoms occurred during the previous 3 maintenance visits.', 'The length of observation will be extended beyond 90 minutes if symptoms of allergic', 'reaction develop as follows:', 'Mild symptoms: observe for 90 minutes or at least 1 hour after symptoms resolve,', 'whichever is longer.', 'Moderate symptoms: observe for at least 2 hours after symptoms resolve.', 'Severe symptoms: observe for at least 3 hours after symptoms resolve either at the', 'study site or an emergency facility, as appropriate. Consider extended overnight', 'observation for subjects experiencing protracted symptoms.', 'The assessing physician will determine whether the allergy symptoms meet the criteria for', 'dose-limiting symptoms (Section 8.5.1.2).', 'The severity of symptoms of an allergic reaction will be assessed as described in Section 8.4.', 'Signs and symptoms of allergic reactions will be recorded on the case report form and in the', \"subject's source documents.\", '8.5.1.1', 'Assessment of Anaphylaxis', 'Anaphylaxis is defined by a number of signs and symptoms, alone or in combination, that', 'occur within minutes up to a few hours after exposure to a provoking agent. Anaphylaxis', 'can be mild, moderate, or severe (Section 8.4). Adverse events of anaphylaxis are considered', 'adverse events of interest and require rapid reporting as described in Section 8.6.2.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 51 of 122', 'Anaphylaxis is likely when any of the following 3 criteria for suspected anaphylaxis is', 'fulfilled (adapted from Sampson, 2006):', '1. Acute onset of an illness (minutes to hours) with involvement of the skin, mucosal tissue,', 'or both (eg, generalized hives, pruritus or flushing, swollen lips/tongue/uvula) and at least', '1 of the following:', 'Respiratory compromise (eg, dyspnea, wheeze/bronchospasm, stridor, reduced PEFR,', 'hypoxemia)', 'Reduced blood pressure or associated symptoms of end-organ dysfunction', '(eg, hypotonia, syncope, incontinence)', '2. Two or more of the following that occur rapidly after exposure to a likely allergen for the', 'subject (minutes to hours):', 'Involvement of the skin/mucosal tissue (eg, generalized hives, itch/flush, swollen', 'lips/tongue/uvula)', 'Respiratory compromise (eg, dyspnea, wheeze/bronchospasm, stridor, reduced PEFR,', 'hypoxemia)', 'Reduced blood pressure or associated symptoms (eg, hypotonia, syncope,', 'incontinence)', 'Persistent GI symptoms (eg, nausea, crampy abdominal pain, vomiting)', '3. Reduced blood pressure after exposure to a known allergen for the subject (minutes to', 'hours) as follows:', 'Infants and children: > 30% decrease from baseline in systolic blood pressure or low', 'systolic blood pressure in children defined as follows:', '- Age 1 to 10 years: < (70 mm Hg + [2 X age])', '- Age 11 to 17 years: < 90 mm Hg', '8.5.1.2 Assessment of the Tolerability of a Study Product Dose or Dose Level', 'The tolerability of a study product dose or dose level will be assessed based on the', 'occurrence of acute allergy symptoms after dosing. When multiple symptoms are present,', 'the severity of the most severe symptom will be used to determine whether symptoms are', 'dose limiting and the dose or dose level is tolerated. Possible assessments of symptom', 'severity, dose-limiting symptoms, and dose tolerability are shown in Table 12.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 52 of 122', 'Table 12: Allergy Symptom Severity and Study Product Dose Tolerability', 'Symptom Severity', 'Dose-Limiting Symptom', 'Assessed Tolerability of Dose', 'None', 'No', 'Tolerated', 'Mild, oropharyngeal symptoms only', 'No', 'Tolerated', 'Mild, meeting tolerability criteria', 'No', 'Tolerated', 'Mild, not meeting tolerability criteria', 'Yes', 'Not tolerated', 'Moderate, with rare exceptions', 'Yes', 'Not tolerated', 'Severe', 'Yes', 'Not tolerated', 'No Symptoms: A study product dose associated with no allergy symptoms will be assessed', 'as tolerated.', 'Mild symptoms: For a study product dose associated with mild allergy symptoms,', 'investigator assessment is essential in determining if the symptoms are dose limiting. Based', 'on experience with study product, mild symptoms are not dose limiting if they meet all of the', 'tolerability criteria as follows:', 'Are isolated to a single organ system', 'Resolve with no medications or with 2 doses of oral H1 antihistamine', 'Do not require administration of epinephrine', 'Do not worsen in intensity or distribution over time', 'Resolve or show definite signs of resolving in under 1 hour', 'Do not include objective wheezing', 'The study product dose is to be considered not tolerated if mild symptoms do not meet the', 'tolerability criteria as follows:', 'Occur in 2 or more organ systems', 'Require treatment with 3 doses of oral H1 antihistamine or 1 dose of epinephrine', 'Progress in severity or distribution over time', 'Continue longer than expected', 'Include objective wheezing', 'If a study product dose associated with mild symptoms that do not meet the tolerability', 'criteria is assessed as tolerated by the investigator, an explanation must be provided on the', 'case report form.', 'Guidelines for recurrent mild symptoms:', 'GI symptoms were the most common subacute, chronic, and recurrent potential', 'symptoms of allergy in phase 2 and 3 clinical studies of AR101.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 53 of 122', 'Study product may worsen pre-existing atopic dermatitis, seasonal allergies, or', 'asthma, or these symptoms may occur as nonacute allergic reactions to study product.', 'Recurrent mild symptoms during several days of dosing at home suggest that the', 'study product dose level is likely not tolerated, even if the symptoms meet the', 'tolerability criteria. For mild dose-related symptoms occurring > 7 times within', '2 weeks, the dose level is to be considered not tolerated.', 'Moderate symptoms: A study product dose associated with moderate allergy symptoms', 'will be assessed as not tolerated, except on rare occasions such as a transient, self-limited', 'symptom in a single organ system that requires no intervention, resolves completely, and is', 'typically subjective.', 'If a study product dose associated with moderate symptoms is assessed as tolerated by the', 'investigator, an explanation must be provided on the case report form.', 'Severe symptoms: A study product dose associated with severe allergy symptoms will be', 'assessed as not tolerated.', '8.5.2', 'Treatment of Allergic Reactions', 'Treatment of allergic reactions is guided by the type of symptoms and severity as determined', 'by the investigator, and supplements dose adjustment. Rescue medications for acute allergic', 'reactions include antihistamines, epinephrine, IV fluids, a beta-agonist (eg, albuterol by', 'inhaler or nebulizer), oxygen, and glucocorticosteroids as indicated (Section 7.3).', 'Mild acute allergic reactions are mostly transient and self-limiting and require no therapeutic', 'intervention, whereas other reactions may require treatment (generally antihistamines).', 'Treatment for chronic or recurrent allergic reactions should be used minimally and', 'discontinued as soon as clinically appropriate. Treatment for chronic or recurrent allergic', 'reactions should not be started in advance of symptoms; however, exceptions may be allowed', 'on a case-by-case basis following approval from the medical monitor.', 'Moderate acute allergic reactions will generally require therapeutic intervention; some rare', 'events may be so transient that no specific treatment is required. For moderate reactions', 'requiring treatment, antihistamines and/or epinephrine is to be administered as indicated.', 'Severe acute allergic reactions will generally require treatment with epinephrine.', 'If the severity of the reaction is uncertain, epinephrine administration is likely appropriate.', 'A medical monitor will be available to answer questions or to assist in decisions related to', 'the study protocol.']", "completion": ""}